Osteoporosis Drugs: Technologies and Global Markets
Report Highlights
- The global market for drugs that treat and prevent osteoporosis was estimated at $8 billion in 2009. This market is projected to grow at a compound annual growth rate (CAGR) of 3.8% to reach $9.7 billion in 2014.
-
The U.S. market for osteoporosis drugs is the largest geographical segment by revenues. This market was worth $3.9 billion in 2009 and is expected to increase at a compound annual growth rate (CAGR) of 4.5% to reach $4.8 billion in 2014.
- The European Union (EU) market was valued at $2.5 billion in 2009 and is projected to increase at a compound annual growth rate (CAGR) of 2.5% to reach $2.8 billion in 2014.
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This study intends to provide readers with an understanding of the global market for prescription drugs that treat and prevent osteoporosis. The study describes the industry structure and major participants in the osteoporosis drugs market, market dynamics and competitive aspects, current developments and future market trends, to assist in understanding the market and identifying areas of commercial interest and potential in osteoporosis.
The study provides an assessment of the current market status, along with an analysis of the patient population, marketed drugs, market revenues, and company shares. The unmet needs of the osteoporosis market, and the challenges that companies must overcome to compete in this market, along with the future trends that shape the industry are also discussed. Future market revenues are forecast for the global market, major drug classes, and largest geographical regions. The study also reviews the compounds currently being investigated in clinical studies for the treatment of osteoporosis.
REASONS FOR DOING THE STUDY
Osteoporosis is a skeletal disorder experiencing increasing prevalence globally, due mainly to the aging of the population and the increasing life expectancy worldwide. Osteoporosis fractures are a major cause of disability and morbidity, particularly among older people, and lead to decreased quality of life and increased costs due to disability and need for assisted living. The market for osteoporosis drugs is large, with global revenues exceeding $8.4 billion in 2008, and projected to grow. Prescription drugs for this indication could have great commercial success; four currently marketed drugs in this indication had global revenues of more than $1 billion at some point in their lifecycle. Additionally, several new drugs are projected to enter the market through 2014 and are expected to contribute to the overall osteoporosis market growth.
SCOPE OF REPORT
The report intends to provide a current market snapshot and future developments in the osteoporosis drugs market covering the period from 2007 through 2014. The report describes the existing drug classes approved for these indications, including bisphosphonates, selective estrogen receptor modulators (SERMs), parathyroid hormones (PTHs), calcitonins, dual-action bone agents (DABAs), and hormone replacement therapies (HRTs). The pipeline of drugs in clinical trials for these indications is also presented and analyzed.
The report includes the following major sections:
- Disease overview
- Patient population analysis
- Industry structure and competitive analysis, including tiers of competition, competitive factors, market unmet needs, challenges, and trends
- Overall market revenue forecast, as well as revenue forecast by major drug classes and geographical regions
- Global market shares and by geographical regions
- In-depth analyses of current drug classes and profiles of major drugs
- Reviews and analyses of compounds in clinical trials, with an emphasis on drugs in advanced stages of development
METHODOLOGY
The analyses and data presented in this report are based on information collected from a variety of industry sources, including pharmaceutical manufacturers and end users. Secondary information sources include company financials and documentation, Securities and Exchange Commission (SEC) filings, trade organizations and publications, online databases, and medical and scientific literature.
The base year for analysis and forecast is 2008. Revenue forecasts are provided for the period of 2009 to 2014. The forecasts are based on a comprehensive analysis of a variety of market and product-specific factors, including historical, current, and future trends; existing and undiagnosed patient population; unmet market needs; existing products patent expiration dates; the threat of generic substitution; new market entrants; and their value proposition and differentiation.
INTENDED AUDIENCE
This report provides information that is useful for business planners, market researchers, marketers, business developers, investors, venture capitalists, consultants, and anyone who wants to understand or invest in this market. The information is also useful for technology licensing and scientific research and development purposes.
INFORMATION SOURCES
The analysis and data presented in this report are based on information collected from a variety of industry sources, including the pharmaceutical manufacturers that currently market prescription drugs in this therapeutic area and research-based companies that develop new drug candidates for these indications, as well as end users of prescription drugs. Secondary information sources include company websites, financials, and other literature; U.S. SEC filings; trade organizations and publications; online databases; and medical and scientific literature.
ANALYST CREDENTIALS
Adriana Rusu holds a Master of Business Administration and a Master of Arts in Chemistry degrees from the University of Arizona. She has more than 6 years of experience in market analysis and management consulting for the life-sciences industry. In her previous positions, Adriana consulted for various life-sciences industry players, including major pharmaceutical companies such as Pfizer, Johnson & Johnson, Novartis, and Merck. She has been quoted in various publications, including Pharma Drug Discovery, Chemistry and Industry, and Drug Discovery News. Adriana has also worked for several years in scientific research and development and quality control for the chemicals industry.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
